Senores Pharmaceuticals IPO Subscription Status
Senores Pharmaceuticals IPO received bids for 79,72,31,944 shares against 85,34,681 offered, an overall subscription of 93.41x at the close of bidding (24 Dec 2024). NII leads at 96.11x.
Last updated · day 3 figures
- Retail
- 89.23x
- NII
- 96.11x
- QIB
- 94.66x
- Total
- 93.41x
Where the demand is
Senores Pharmaceuticals IPO subscription by category
| Category | Shares offered | Shares bid | Amount bid | Subscription |
|---|---|---|---|---|
| QIB | 45,93,216 | 43,47,78,102 | ₹16,999.82 Cr | 94.66x |
| NII | 23,19,879 | 22,29,63,632 | ₹8,717.88 Cr | 96.11x |
| bNII above ₹10 lakh | 15,46,586 | 14,46,53,764 | ₹5,655.96 Cr | 93.53x |
| sNII ₹2–10 lakh | 7,73,293 | 7,83,09,868 | ₹3,061.92 Cr | 101.27x |
| Retail | 15,46,586 | 13,79,96,088 | ₹5,395.65 Cr | 89.23x |
| Employees | 75,000 | 14,94,122 | ₹58.42 Cr | 19.92x |
| Total | 85,34,681 | 79,72,31,944 | ₹31,171.77 Cr | 93.41x |
* Shares Offered and Total Amount are calculated based on the upper price of the issue price range. * The portion of anchor investors (or market makers) is not included in the total number of shares offered.
Senores Pharmaceuticals IPO subscription day-wise
| Category | Day 3 |
|---|---|
| QIB | 94.66x |
| NII | 96.11x |
| bNII | 93.53x |
| sNII | 101.27x |
| Retail | 89.23x |
| Employees | 19.92x |
| Total | 93.41x |
| Total added | 93.41x |
Cumulative figures at the end of each day. Read across a row to see how demand built up. Shading deepens as subscription rises above 1x; "Total added" is how much overall subscription grew that day.
Senores Pharmaceuticals IPO reservation
| Category | Shares | Share of issue |
|---|---|---|
| Qualified Institutional Buyers | 45,93,216 | 53.82% |
| Non-Institutional Investors | 23,19,879 | 27.18% |
| bNII · above ₹10 lakh | 15,46,586 | 67% of NII |
| sNII · ₹2–10 lakh | 7,73,293 | 33% of NII |
| Retail Individual Investors | 15,46,586 | 18.12% |
| Employee reservation | 75,000 | 0.88% |
| Public issue | 85,34,681 | 100% |
Allotment Chances Note
These are estimates from the latest application and subscription figures. Actual chances are usually somewhat better, because:
- Not every bid is at the cut-off price. Bids below the final issue price are rejected before the lottery, so fewer applications compete.
- Multiple-lot applications count once. In an oversubscribed retail or sNII portion, each application gets at most one minimum lot in the draw, however many lots it bid for.
- Invalid applications drop out. Unapproved UPI mandates, PAN mismatches and duplicate applications are removed before allotment.
Applying for more lots in the retail category does not improve your odds; applying from separate family accounts does.
Senores Pharmaceuticals IPO subscription: FAQs
- What is the overall subscription of Senores Pharmaceuticals IPO?
- Senores Pharmaceuticals IPO is subscribed 93.41x overall as of day 3 (24 December 2024), with bids for 79,72,31,944 shares against 85,34,681 offered.
- What is the retail subscription of Senores Pharmaceuticals IPO?
- The retail portion is subscribed 89.23x as of day 3 (24 December 2024).
- What is the QIB and NII subscription of Senores Pharmaceuticals IPO?
- QIBs have subscribed 94.66x of their portion, and NIIs 96.11x (bNII 93.53x, sNII 101.27x) as of day 3 (24 December 2024).
- How can I check Senores Pharmaceuticals IPO subscription status live?
- This page shows category-wise and day-wise figures and is updated during bidding hours. The same data is published on the BSE and NSE websites under the issue name.
- How do I apply for Senores Pharmaceuticals IPO?
- Apply online through your broker or bank using UPI or ASBA. Choose the IPO, enter the number of lots and bid price (retail investors can bid at the cut-off price), and approve the UPI mandate before the issue closes on 24 December 2024.
Subscription figures are compiled from BSE and NSE bid data and can be revised by the exchanges after the issue closes. For information only; not investment advice.